Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

Volumn , Issue , 2014, Pages 149-153

  Raghupathy, Radha ^a   Hui, Edwin P un ^a   Chan, Anthony T ak Cheung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CANCER VACCINE; HERPES VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; CHINA; DRUG EFFECTS; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; EPSTEIN-BARR VIRUS INFECTIONS; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; NASOPHARYNGEAL NEOPLASMS; PATHOGENICITY; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CANCER VACCINES; CHINA; ENDEMIC DISEASES; EPSTEIN-BARR VIRUS INFECTIONS; GENETIC THERAPY; HERPESVIRUS 4, HUMAN; HERPESVIRUS VACCINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INCIDENCE; NASOPHARYNGEAL NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84908276736     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.14694/EdBook_AM.2014.34.149     Document Type: Review

References (0)